TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com

Share Article

RnRMarketResearch.com adds “TS-1 (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store. This report focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market.

TS-1 Colorectal Cancer Market

TS-1 Colorectal Cancer Market

The report “TS-1 (Colorectal Cancer) – Forecast and Market Analysis to 2023” focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market. TS-1 is an anti-cancer drug which is typically used for treating colorectal cancer. It is administered orally and is also used for treating gastric cancer and pancreatic cancer. TS-1 is composed of tegafur, gimestat and otastat potassium. The drug was first approved in 1999 in Japan for the treatment of gastric cancer. TS-1 is a member of the fluoropyrimidine class of chemotherapeutic agents and it is the first anti-cancer agent in orally disintegrating tablet form. Complete Report is Available @ http://www.rnrmarketresearch.com/ts-1-colorectal-cancer-forecast-and-market-analysis-to-2023-market-report.html .

Taiho Pharmaceutical’s TS-1 is a combination chemotherapy that consists of tegafur (a pro-drug of 5-FU) and two agents, gimeracil and oteracil, which decrease the rate of degradation of the 5-FU anti-metabolite. TS-1 was originally approved for the treatment of gastric cancer in Japan in 1999.The drug subsequently gained Japanese approval for colorectal cancer in 2003, and is also approved for other indications, including NSCLC and breast cancer. TS-1 is not approved for the treatment of CRC in the US or 5EU, and no late-stage trials for this indication are currently ongoing in these regions.

Reasons to Buy

  •     Understand and capitalize by identifying products that are most likely to ensure a robust return
  •     Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
  •     Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  •     Make more informed business decisions from insightful and in-depth analysis of TS-1 performance
  •     Obtain sales forecast for TS-1 from 2013-2023 in top country (Japan)

Order a Purchase copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=251698 .

Table of Contents

1 Table of Contents
1.1 List of Tables

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Clinical Staging
3.3 Symptoms

4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Screening and Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice

5 Competitive Assessment
5.1 Overview

6 TS-1 (Tegafur, Gimeracil, Oteracil)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast

7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Diagnosed Colorectal Cancer Patients
7.4.2 Percent Drug-Treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Average Body Weight and Surface Area Across the 8MM
7.4.5 Individual Drug Assumptions
7.4.6 Generic Erosion
7.5 Primary Research - KOLs Interviewed for this Report
7.6 Primary Research - Prescriber Survey
7.7 About the Authors
7.7.1 Analyst
7.7.2 Global Head of Healthcare
7.8 About GlobalData
7.9 Disclaimer

List of Tables
Table 1: TNM and Staging Classification System for CRC
Table 2: Symptoms of Colorectal Cancer
Table 3: Treatment Guidelines for CRC
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
Table 6: Leading Treatments for CRC, 2014
Table 7: Product Profile - TS-1
Table 8: TS-1 SWOT Analysis, 2014
Table 9: Global Sales Forecasts ($m) for TS-1, 2013-2023
Table 10: Average Body Weight and Surface Area Across the 8MM
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Explore more reports on Cancer Drugs industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
Follow >
Market Reports China
Like >
Follow us on
Visit website